Novartis AG (0QLR)
London Exchange · UK · prices in GBP · close of 19 Oct 2026
Key indicators
| Last close | GBP 124.61 |
|---|---|
| 52-week range | 97.10 – 132.64 |
| Return, 1 month / 3 months | +7.3% / −1.5% |
| Return, 1 year / 3 years | +21.1% / +42.1% |
| Trend | Uptrend |
| RSI (14) | 63 |
| Volatility (1 year) | 22.4% |
| Worst drawdown (1 year) | -15.4% |
| Average daily value traded | 128.01M GBP |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Novartis is a pharmaceutical company based in Basel, Switzerland. It develops and sells prescription medicines, with major areas including cancer treatments, heart and circulation medicines, and drugs for the nervous system and eye conditions. Its customers are hospitals, doctors, pharmacies and patients in many countries around the world. The company also has a generics business that supplies lower-cost copies of medicines. Novartis carries out research and manufacturing across several regions and sells its products through its own commercial teams and partners.
Novartis AG trades under the code 0QLR on the London Exchange in UK, with its price quoted in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Novartis AG (0QLR) trades on the London Exchange in UK. It last closed at GBP 124.61 on 19 October 2026.
Its price-based Market X-Ray is 71 out of 100 (a strong price profile), ranking 424 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 21.1% and over the last three months it fell 1.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 62 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.3% | ||
| From 52-week high | -5.2% | ||
| Momentum | 58 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -1.5% | ||
| 6-month return | 7.3% | ||
| 12-month return, skipping the last month | 12.8% | ||
| Stability (higher is calmer) | 83 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 22.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -15.4% | ||
| Liquidity | 90 · Strong | Trades actively. | |
| Average daily value traded | 128.01M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +3.9% |
|---|---|
| 1 month | +7.3% |
| 3 months | −1.5% |
| 6 months | +7.3% |
| 1 year | +21.1% |
| 3 years | +42.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 121.26 / 120.66 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.62 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 10 Mar 2025 | GBX 0.0350 |
| 7 Mar 2024 | GBX 0.0330 |
| 9 Mar 2023 | GBX 0.0303 |
| 8 Mar 2022 | GBX 0.0294 |
| 4 Mar 2021 | GBX 0.0284 |
| 3 Mar 2020 | GBX 0.0280 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.